Marios Fotiadis

Advent invests in companies located across the globe. The firm targets companies operating in the fields of business & financial services, healthcare, industrial and technology services. It provides financing for leveraged buyout, recapitalizations, growth and public to private transactions. It also acquires majority and minority ownership.

Develops and manufactures novel small molecule medicines

Discovers, develops and commercializes treatments for infectious diseases

Functions as a College/University

TVM Capital invests in companies located in the United States and Europe. The firm focuses on information technology, communications and life sciences sectors. It provides financing for early and later stage capital requirements. It also acts as lead or co-lead investor.

Cowen Capital Partners (CCP) focuses on equity investments in businesses that are undergoing ownership transitions, divestitures, MBOs or recapitalizations, as well as companies that need financing for growth initiatives. The firm prefers to make control investments, but will partner with other investors and make selective minority investments depending on the specific terms of the opportunity. They can structure transactions to accommodate the objectives of all constituents involved including sellers, investors and managers. CCP invests in a variety of sectors, but tends to focus on business services, healthcare services, specialty manufacturing and selected turnaround situations. The firm looks for companies with: (1) proven business models (2) strong management teams (3) revenues of at least $10 million (4) annual organic growth rates greater than 10%. (5) defined market positions and (6) defensible market niches. CCP seeks to invest in companies with high return uses of capital, such as facility or capacity expansion to accommodate proven demand, implementation of a new product line or complimentary services and/or the consolidation of a fragmented industry with clear synergies. Targeted buyout transactions typically range in valuation from $30 million to $200 million and exhibit strong free cash flow (EBITDA in the $5 million to $20 million range). CCP is careful in the capitalization of transactions, using leverage to enhance investor and management returns while ensuring the company has the appropriate capital to achieve its long-term objectives.

Develops pharmaceutical products

Enterprise partners seeks investment opportunities in companies located in the US, primarily in California and New York and also makes invests in Canada. The firm targets companies operating in the fields of telecommunications, life sciences and enterprise software. The firm provides financing for buyout, seed, early and later stage capital requirements with an initial investment of $0.3 million in seed stage and invests up to $3 - $10 million in follow on investments. They acts as a lead investor and makes co-investments. They also takes a seat on the board of directors.

Functions as a College/University